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Abstract
Objectives The aim of the present study was to investigate the
effects of Osteogain, a new formulation of enamel matrix de-
rivative (EMD) in combination with a grafting material on a
wide variety of genes for cytokines, transcription factors
and extracellular matrix proteins involved in osteoblast
differentiation.
Materials and methods Primary human periodontal ligament
(PDL) cells were seeded on natural bone mineral (NBM) par-
ticles coated with Osteogain for 24 h and analyzed for regu-
lated gene expression using a human osteogenesis gene super-
array kit. Osteoblast-related genes include those transcribed
during bone mineralization, ossification, bone metabolism,
cell growth and differentiation as well as gene products
representing extracellular matrix molecules, transcription fac-
tors and cell adhesion molecules.
Results Osteogain significantly upregulated the expression of
over 20 of the 100 genes examined including bone morpho-
genetic protein 2 (BMP2), TGFβ1, fibroblast growth factor
(FGF), epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF) as well as some of their associated
receptors. Osteogain also promoted gene expression of a
number of osteoblast differentiation markers including
collagen1α2 and alkaline phosphatase as well as cell adhesion
molecules including fibronectin and a variety of integrin bind-
ing proteins. Interestingly, Osteogain promoted calcitonin re-
ceptor 55-fold and also promoted annexin A5 gene expression
over 12-fold.
Conclusion The present study demonstrates that Osteogain is
capable of either upregulating or downregulating the expres-
sion of a wide variety of genes including those for growth
factors and cytokines when combined with a bone grafting
material.
Clinical relevance The results from the present study demon-
strate the large and potent effect of addition of Osteogain in
combination to a bone grafting material over a wide variety of
genes supporting osteogenesis.
Keywords Enamelmatrix derivative . Enamel matrix
proteins . Emdogain . Periodontal regeneration . Bone graft
Introduction
Enamel matrix derivative (EMD) has been shown to promote
periodontal regeneration by inducing new root cementum,
periodontal ligament and alveolar bone formation as well as
to speed up tissue wound healing [1–4]. The major compo-
nents of EMD are amelogenins, a family of hydrophobic pro-
teins that account for more than 95 % of the total protein
content [5]. These proteins self-assemble into supramolecular
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aggregates that form an insoluble extracellular matrix that
function to control the ultrastructural organization of the de-
veloping enamel crystallites [5]. Other proteins found in the
enamel matrix include enamelin, ameloblastin (also called
amelin or sheathlin), amelotin, apin and various proteinases
[6, 7]. The rationale for the clinical use of EMD is the obser-
vation that enamel matrix proteins (EMPs) are deposited onto
the surface of developing tooth roots prior to cementum for-
mation [8].
Although histological studies in animals and humans have
provided evidence for periodontal regeneration and substan-
tial clinical improvements following the use of EMD (com-
mercially available under the trademark name Emdogain;
Straumann AG, Basel, Switzerland), concerns have been
expressed regarding the viscous nature of Emdogain gel,
which may not be sufficient to prevent flap collapse in peri-
odontal defects with a complicated anatomy [9, 10]. In order
to overcome this potential limitation and improve the clinical
outcomes, various combinations of Emdogain and different
types of grafting materials have been used [1]. The combina-
tion of Emdogain with a natural bone mineral (NBM) of bo-
vine origin has provided increased periodontal regeneration
power and substantial clinical improvements when compared
to either NBM alone or Emdogain alone [1]. Recently, a new
carrier system for enamel matrix derivative was designed to
improve protein adsorption of enamel matrix proteins to
grafting materials [11–13]. In a pioneering study, it was found
that more proteins are adsorbed on the material surface when
EMD was delivered in liquid formulation when compared to
the gel formulation found in Emdogain [11]. Advantages also
included better surface coating of the protein and penetration
of EMPs within the bone grafting material surface [11]. Fol-
lowing preliminary experiments, a new carrier system was
developed in liquid formulation for EMD (Osteogain;
Straumann AG). The aim of the present study was therefore
to investigate the effects of Osteogain in combination with
NBM on the initial periodontal ligament (PDL) cell behaviour
when compared to NBM alone by assessing the gene expres-
sion of a wide variety of osteoblast cytokines, growth factors,
differentiation markers and extracellular matrix molecules
using a commercially available super-array kit.
Methods
Osteogain and bone grafting material
For all in vitro experiments, Osteogain (0.3-ml vials, working
concentration 30 mg/ml) was kindly provided by Straumann
AG, Malmo, Sweden. In order to reach the in vitro working
concentration of 100 μg/ml, Osteogain was diluted in cell
culture media containing 10 % FBS. For all in vitro cell ex-
periments, cells were exposed to culture media containing
Osteogain at time point 0 until the end of the experiment. A
NBMbone graftingmaterial (Bio-Oss, Geistlich, Switzerland)
was utilized as the material of choice for the present study due
to our laboratories previously handling its use as well as its
ability to adsorb enamel matrix proteins within the material
graft [11].
PDL cell isolation and differentiation
Primary human PDL cells were isolated from the middle third
of extracted premolars for orthodontic reasons from patients
demonstrating no signs of periodontal disease as previously
described [14, 15]. Informed consent was obtained from all
the participants. Primary PDL cells were detached from the
tissue culture plastic using trypsin solution. Cells used for
experimental seeding were from passages 4–6. Primary PDL
cells were seeded at a density of 500,000 cells on top of
500 mg NBM material per well in 6-well dishes for super-
array analysis. Assays were performed in quadruplicates with
four independent experiments performed from four different
human donors.
Super-array of osteogenic potential
The initial expression of osteoblast-related genes was exam-
ined after culture of cells for 24 h. Total RNA was isolated
using TRIzol reagent and RNeasy Mini Kit (QIAGEN, Basel,
Switzerland). ATaqMan®HumanOsteogenesis 96-well Plate
Super-array (4414096; Applied Biosystems, Rotkreuz, Swit-
zerland) was employed for the analysis. Osteoblast-related
genes include those transcribed during bone mineralization,
ossification, bone metabolism, cell growth and differentiation.
The gene products represent extracellular matrix molecules,
transcription factors and cell adhesion molecules among
others. Real-time RT-PCR was performed according to the
manufacturer’s protocol using the 20 μl final reaction volume
of TaqMan® One-Step Master Mix Kit (Applied Biosystems)
as previously described [16]. RNA quantification was per-
formed using a NanoDrop 2000c (Thermo Scientific, Wal-
tham, MA, USA), and 100 ng of the total RNAwas used per
sample well. A gene fold increase represents data from cells
grown in the presence of NBM particles precoated or not with
Osteogain.
Statistical analysis
Gene array analysis was performed for both control (n=4) and
Osteogain (n= 4) groups. Means and standard deviations
(SDs) were calculated, and the statistically significant differ-
ences were examined by Student’s t test between both groups
(*p values <0.05 was considered significant).
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Results
The full set of genes investigated in the present study is listed
in Table 1 in alphabetical order. As depicted, a number of
genes involved in osteogenesis were upregulated with the vast
majority between 1- and 10-fold when cells were cultured in
the presence of Osteogain (Table 1). For the purpose of this
experiment, only genes having been upregulated over 3-fold
or those that demonstrated a significance of greater than a p
value of 0.05 are discussed. Alpha-2-HS-glycoprotein was
upregulated 5.09-fold with a p value of 0.002. Alkaline phos-
phatase and annexin 5 were upregulated [3.19 (p=0.022) and
12.08 (p=0.001), respectively]. From the number of tested
bone morphogenetic proteins (BMPs), bone morphogenetic
protein 2 (BMP2) showed the highest upregulation of 6.96
(p=0.039) with its associated receptor upregulated 3.09-fold
when compared to control cells seeded on NBM alone. Inter-
estingly, the addition of Osteogain upregulated calcitonin re-
ceptor 55.95-fold (p=0.008). Both epidermal growth factor
(EGF) and fibroblast growth factor (FGF) demonstrated in-
creased expression with their associated receptors being up-
regulated also (Table 1). Fibronectin, a cell attachment pro-
tein, was upregulated 3.4-fold (p= 0.018). A number of
integrin binding proteins were upregulated between 2.6- and
9.04-fold (Table 1). Platelet-derived growth factor (PDGF)
was upregulated 1.74-fold; however, this demonstrated statis-
tically significant differences from control (p = 0.019).
SMAD1 and SMAD2, members of intracellular pathways
for BMPs, were significantly upregulated 1.89- and 2.62-fold
(p<0.05). Lastly, both Twist homolog 1 and vitamin D were
both upregulated 2.66- and 5.58-fold, respectively, with both
demonstrating significant differences from controls (p=0.025
and p=0.047, respectively).
Discussion
The aim of the present study was to investigate the role of
Osteogain when combined with bone grafting materials in
comparison to NBM alone on a wide array of genes related
to osteogenesis. As such, the use of a gene array with a
predesigned set of roughly 100 genes was utilized in order
to determine possible mechanisms/roles of enamel matrix pro-
teins on osteoblast differentiation. Interestingly, of the 100
genes investigated, 21 genes demonstrated either a 3-fold up-
regulation or a p<0.05 when compared to control samples
(Table 1). Many of these genes were upregulated between 2-
and 10-fold.
One of the surprising results from this study was that cal-
citonin receptor was upregulated over 55-fold following the
addition of Osteogain to a bone grafting material. Calcitonin
has several roles in the body. More specifically, it is responsi-
ble for lowering blood Ca2+ primarily by inhibiting osteoclast
activity and stimulating osteoblast activity [17]. Furthermore,
what is impressive about these results is that we used different
primary PDL cells from four different human donors. Thus,
this significant upregulation is independent of slight human
variations and it seems plausible that Osteogain may have
some effect and/or some regulation through calcitonin/
calcitonin receptors. Furthermore, a second gene for which
was most significantly upregulated was annexin A5 with a
12.08-fold increase when treated with Osteogain. Annexin
A5 is a calcium-dependent phospholipid binding protein
which has been suggested to play a role as a mechanosensitive
ion channel [18]. Disruption of its expression impairs mechan-
ically induced calcium signalling in osteoblasts, and it has the
ability to interact with both extracellular matrix proteins and
cytoskeletal elements [18]. Thus, the pairing of upregulated
genes calcitonin receptor and annexin A5 suggests a possible
role of calcium regulation via enamel matrix proteins. Further
investigations in this area are necessary.
The use of Osteogain also elicited a significant upregula-
tion of many growth factors and their associated receptors
(Table 1). Of the group of BMPs, BMP2 was the most upreg-
ulated with a significant increase of 6.96-fold when treated
with Osteogain+NBM in comparison to NBM alone (Table
1). Furthermore, both bone morphogenetic protein receptor 2
and intracellular protein SMAD2 were upregulated 3.07- and
2.69-fold, respectively. Thus, the present study reveals that
enamel matrix proteins have a significant influence on the
BMP/cell signalling events that take place following cell cul-
ture with Osteogain. This is in accordance with previous pub-
lications that have demonstrated this phenomenon [19–21].
The family of SMAD signal proteins are found in many cell
types and are responsible for transducing extracellular signals
from TGFβ and BMPs from the cell membrane to the nucleus
[22]. Kawase et al. showed in two consecutive studies that
EMD was able to induce rapid translocation of SMAD2 to
the nucleus and this was responsible for increased cell prolif-
eration [23, 24]. In the present study, we also observed a
significant increase of SMAD2 by 2.69-fold in as short as
24 h following exposure to Osteogain (Table 1).
Apart from BMP signalling, it was also found that gene
expressions of TGFβ1, PDGF, EGF and FGF were all upreg-
ulated in response to Osteogain (Table 1). Furthermore, the
associated receptors of both EGF and FGF were also upregu-
lated. This is in accordance with our previously published
gene array which has demonstrated the large effects of EMD
on many growth factors, cytokines and their associated recep-
tors [20]. Thus, this study further confirms the effects of
Osteogain as opposed to gel-like substance Emdogain and
demonstrates its ability to elicit a large effect on gene expres-
sion from primary human PDL cells.
Interestingly, Osteogain was also able to have effects on
cell adhesion molecules including fibronectin and various
integrin binding proteins (Table 1). Fibronectin is a known
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Table 1 Osteogenic gene array of primary PDL cells exposed to Osteogain in combination with NBM bone graft in comparison to NBM alone








ACVR1 Activin A receptor, type I −7.80 −7.47 1.25 0.915332
AHSG Alpha-2-HS-glycoprotein −11.85 −9.51 5.09 0.001627
ALPL Alkaline phosphatase, liver/bone/kidney −9.80 −8.13 3.19 0.021668
ANXA5 Annexin A5 −9.36 −5.76 12.08 0.000579
BGLAP Bone gamma-carboxyglutamate (gla) protein −2.41 −2.82 0.75 0.620107
BGN Biglycan −6.86 −7.30 0.74 0.596608
BMP1 Bone morphogenetic protein 1 −3.08 −4.07 0.51 0.247237
BMP2 Bone morphogenetic protein 2 −7.12 −4.32 6.96 0.038526
BMP3 Bone morphogenetic protein 3 −3.56 −3.48 1.06 0.596056
BMP4 Bone morphogenetic protein 4 −4.00 −3.61 1.31 0.228776
BMP5 Bone morphogenetic protein 5 −9.34 −9.17 1.13 0.673938
BMP6 Bone morphogenetic protein 6 −10.05 −9.89 1.11 0.734613
BMP7 Bone morphogenetic protein 7 −3.29 −2.29 1.99 0.202071
BMPR1A Bone morphogenetic protein receptor, type IA −3.60 −3.87 0.83 0.942792
BMPR1B Bone morphogenetic protein receptor, type IB −12.16 −10.98 2.27 0.208567
BMPR2 Bone morphogenetic protein receptor, type II
(serine/threonine kinase)
−4.80 −3.18 3.07 0.145458
CALCR Calcitonin receptor −9.28 −3.47 55.95 0.007783
CD36 CD36 molecule (thrombospondin receptor) −3.90 −4.72 0.56 0.439813
CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) −6.06 −6.89 0.56 0.778036
CHRD Chordin −11.23 −11.17 1.04 0.343664
COL10A1 Collagen, type X, alpha 1 −12.43 −11.34 2.13 0.460268
COL14A1 Collagen, type XIV, alpha 1 −7.23 −5.96 2.42 0.463013
COL15A1 Collagen, type XV, alpha 1 −7.84 −6.37 2.76 0.337634
COL1A1 Collagen, type I, alpha 1 −5.50 −5.52 0.99 0.977061
COL1A2 Collagen, type I, alpha 2 −12.75 −11.14 3.06 0.822122
COL2A1 Collagen, type II, alpha 1 −6.53 −7.49 0.51 0.072133
COL3A1 Collagen, type III, alpha 1 −3.59 −3.73 0.91 0.793750
COL5A1 Collagen, type V, alpha 1 −2.21 −3.36 0.45 0.243179
COMP Cartilage oligomeric matrix protein −13.01 −13.39 0.77 0.273670
CSF1 Colony-stimulating factor 1 (macrophage) −9.87 −8.68 2.27 0.325348
CSF2 Colony-stimulating factor 2 (granulocyte-macrophage) −1.68 −1.71 0.98 0.950459
CSF3 Colony-stimulating factor 3 (granulocyte) −5.76 −6.45 0.62 0.630748
CTSK Cathepsin K −5.41 −5.97 0.68 0.649570
DLX5 Distal-less homeobox 5 −9.36 −8.41 1.93 0.425777
EGF Epidermal growth factor −13.41 −11.60 3.50 0.035436
EGFR Epidermal growth factor receptor −11.16 −8.51 6.28 0.015134
FGF1 Fibroblast growth factor 1 (acidic) −7.57 −5.38 4.58 0.040644
FGF2 Fibroblast growth factor 2 (basic) −16.41 −15.07 2.54 0.002678
FGFR1 Fibroblast growth factor receptor 1 −2.73 −2.74 0.99 0.928878
FGFR2 Fibroblast growth factor receptor 2 −2.98 −2.08 1.87 0.031555
FLT1 Fms-related tyrosine kinase 1 (vascular endothelial growth
factor/vascular permeability factor receptor)
−6.56 −7.33 0.59 0.338385
FN1 Fibronectin 1 −8.03 −6.26 3.40 0.018460
GDF10 Growth differentiation factor 10 −6.67 −6.01 1.58 0.489789
GLI1 GLI family zinc finger 1 −6.86 −6.86 1.00 0.730111
ICAM1 Intercellular adhesion molecule 1 −7.58 −7.61 0.98 0.596638
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Table 1 (continued)








IGF1 Insulin-like growth factor 1 (somatomedin C) −10.81 −10.31 1.42 0.185206
IGF1R Insulin-like growth factor 1 receptor −6.53 −6.48 1.03 0.968599
IGF2 Insulin-like growth factor 2 (somatomedin A) −3.10 −3.69 0.66 0.553169
IHH Indian hedgehog 1.59 1.23 0.78 0.995198
ITGA1 Integrin, alpha 1 −13.98 −12.60 2.60 0.009439
ITGA2 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) −9.18 −6.01 9.04 0.000284
ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of
VLA-3 receptor)
−13.77 −12.70 2.10 0.003393
ITGAM Integrin, alpha M (complement component 3 receptor 3 subunit) −1.79 −2.06 0.83 0.544331
ITGB1 Integrin, beta 1 (fibronectin receptor, beta polypeptide,
antigen CD29
includes MDF2, MSK12)
0.65 1.16 1.42 0.448769
MMP10 Matrix metallopeptidase 10 (stromelysin 2) −4.23 −4.63 0.76 0.749247
MMP2 Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase,
72 kDa type IV collagenase)
−4.92 −4.88 1.02 0.820871
MMP8 Matrix metallopeptidase 8 (neutrophil collagenase) −5.12 −5.51 0.77 0.619721
MMP9 Matrix metallopeptidase 9 (gelatinase B, 92 kDa gelatinase,
92 kDa type IV collagenase)
−6.82 −6.59 1.17 0.504086
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in
B cells 1
−7.03 −6.10 1.90 0.243775
NOG Noggin −4.77 −4.42 1.28 0.632229
PDGFA Platelet-derived growth factor alpha polypeptide −8.05 −7.26 1.74 0.018625
PHEX Phosphate-regulating endopeptidase homolog, X linked −9.62 −9.33 1.22 0.223625
RUNX2 Runt-related transcription factor 2 −5.28 −5.53 0.84 0.571962
SERPINH1 Serpin peptidase inhibitor, clade H (heat shock protein 47),
member 1 (collagen binding protein 1)
−9.13 −8.93 1.15 0.418260
SMAD1 SMAD family member 1 −9.10 −8.18 1.89 0.019281
SMAD2 SMAD family member 2 −7.81 −6.42 2.62 0.009082
SMAD3 SMAD family member 3 −5.55 −4.31 2.36 0.514189
SMAD4 SMAD family member 4 −4.79 −3.93 1.81 0.250318
SMAD5 SMAD family member 5 −4.42 −4.56 0.91 0.732234
SOX9 SRY (sex-determining region Y)-box 9 −5.49 −5.53 0.97 0.382991
SP7 Sp7 transcription factor −11.41 −10.75 1.58 0.338706
SPP1 Secreted phosphoprotein 1 −11.44 −10.56 1.85 0.593599
TGFB1 Transforming growth factor, beta 1 −10.76 −9.47 2.45 0.214655
TGFB2 Transforming growth factor, beta 2 −1.49 −2.79 0.41 0.039454
TGFB3 Transforming growth factor, beta 3 −2.73 −2.86 0.92 0.884488
TGFBR1 Transforming growth factor, beta receptor 1 −6.57 −7.15 0.67 0.076319
TGFBR2 Transforming growth factor, beta receptor II (70/80 kDa) −5.44 −7.79 0.20 0.171507
TNF Tumour necrosis factor −9.49 −8.05 2.71 0.278587
TNFSF11 Tumour necrosis factor (ligand) superfamily, member 11 −9.43 −7.98 2.72 0.235600
TWIST1 Twist homolog 1 (Drosophila) −12.02 −10.61 2.66 0.024769
VCAM1 Vascular cell adhesion molecule 1 −10.06 −9.62 1.36 0.635539
VDR Vitamin D (1,25-dihydroxyvitamin D3) receptor −9.13 −6.65 5.58 0.046791
VEGFA Vascular endothelial growth factor A −6.57 −5.97 1.51 0.452665
VEGFB Vascular endothelial growth factor B −7.84 −7.62 1.17 0.419889
Italicized values represent significant difference between NBM+Osteogain group versus NBM alone (p< 0.05)
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extracellular matrix protein secreted by various cell types able
to increase cell attachment [25, 26]. Furthermore, the effects
of integrin binding have a long history of well-documented
effects on cell attachment [27, 28]. Previous investigation on
the attachment of human periodontal ligament cells to enamel
matrix-derived protein demonstrated that it is mediated via an
interaction between BSP-like molecules and integrin αvβ3
[29]. Furthermore, other investigators demonstrated that both
PDL and gingival fibroblasts showed increased expression of
the integrin subunits α2, α5 and β1 and integrin αvβ3 follow-
ing cell seeding with enamel matrix derivative.
It must be noted that in the present study, the control of
utilizing Osteogain alone was not evaluated purely to simulate
a clinical setting. Osteogain was developed as a new liquid
carrier system for EMD in order to maximize better adsorption
of enamel matrix proteins onto a bone grafting material sur-
face. Clinically, the combination approach is often utilized due
to the principal reason that Emdogain gel alone is unable to
prevent a flap collapse for large intrabony defects, thus neces-
sitating the combination with a bone grafting material. Clini-
cally, it is also possible to use a bone grafting material alone
for the treatment of large intrabony defects; thus, it was chosen
as a control in the present study. However, the use of
Osteogain alone would never be utilized clinically as the liq-
uid formulation of the material would have handling issues.
For these reasons, Osteogain alone was not used as a second-
ary control. Future investigation following the results from the
present study will determine the effects of Osteogain on cell
behaviour at later time points on specific gene transcription of
osteoblast differentiation markers as well as at the protein
level.
Conclusion
The present study demonstrates the potent effects of
Osteogain when combined with a bone grafting material on
gene expression of many cytokines, growth factors, adhesion
molecules and intracellular signalling proteins. It was found
that Osteogain was able to significantly upregulate BMP2,
TGFβ1, FGF, EGF and PDGF as well as some of their asso-
ciated receptors. Osteogain also promoted a number of osteo-
blast differentiation markers including collagen1α2 and alka-
line phosphatase as well as cell adhesion molecules including
fibronectin and a variety of integrin binding proteins. Further
research analyzing protein quantification and later time points
are now necessary to further investigate the role of Osteogain
on new bone formation.
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